Biomarin Operating Income vs Cost of Revenue Analysis

BMRN Stock  USD 87.34  1.27  1.43%   
Biomarin Pharmaceutical financial indicator trend analysis is way more than just evaluating Biomarin Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biomarin Pharmaceutical is a good investment. Please check the relationship between Biomarin Pharmaceutical Operating Income and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Operating Income vs Cost Of Revenue

Operating Income vs Cost of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biomarin Pharmaceutical Operating Income account and Cost of Revenue. At this time, the significance of the direction appears to have weak relationship.
The correlation between Biomarin Pharmaceutical's Operating Income and Cost of Revenue is 0.35. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Cost of Revenue in the same time period over historical financial statements of Biomarin Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Biomarin Pharmaceutical's Operating Income and Cost of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Biomarin Pharmaceutical are associated (or correlated) with its Cost of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost of Revenue has no effect on the direction of Operating Income i.e., Biomarin Pharmaceutical's Operating Income and Cost of Revenue go up and down completely randomly.

Correlation Coefficient

0.35
Relationship DirectionPositive 
Relationship StrengthVery Weak

Operating Income

Operating Income is the amount of profit realized from Biomarin Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Biomarin Pharmaceutical is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Biomarin Pharmaceutical income statement and represents the costs associated with goods and services Biomarin Pharmaceutical provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most indicators from Biomarin Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Tax Provision is very stable compared to the past year. As of the 29th of March 2024, Enterprise Value Multiple is likely to grow to 74.10, while Selling General Administrative is likely to drop about 246.1 M.
 2021 2022 2023 2024 (projected)
Gross Profit1.4B1.6B1.8B1.9B
Total Revenue1.8B2.1B2.4B2.5B

Biomarin Pharmaceutical fundamental ratios Correlations

0.950.770.861.00.970.6-0.360.550.740.990.320.690.940.760.690.960.880.980.970.950.970.480.750.560.12
0.950.680.810.920.930.62-0.460.550.820.90.270.830.850.810.770.860.850.940.980.860.960.490.790.670.23
0.770.680.530.810.630.290.26-0.080.620.750.190.410.80.410.470.820.660.650.640.850.76-0.050.40.22-0.07
0.860.810.530.840.850.52-0.370.680.610.820.150.490.890.550.310.890.820.850.850.830.870.380.570.440.33
1.00.920.810.840.960.57-0.290.50.720.980.30.650.960.720.650.970.880.970.940.970.960.430.710.520.08
0.970.930.630.850.960.64-0.540.690.710.960.290.730.90.820.720.910.90.990.970.890.940.60.80.630.12
0.60.620.290.520.570.64-0.490.420.070.640.160.490.490.620.570.530.370.640.650.510.520.630.60.77-0.29
-0.36-0.460.26-0.37-0.29-0.54-0.49-0.85-0.27-0.35-0.08-0.59-0.19-0.66-0.52-0.19-0.35-0.53-0.52-0.17-0.35-0.79-0.64-0.65-0.19
0.550.55-0.080.680.50.690.42-0.850.40.540.260.50.460.620.370.450.560.670.660.410.530.760.630.490.4
0.740.820.620.610.720.710.07-0.270.40.660.250.770.680.650.630.670.80.710.770.690.820.210.640.330.49
0.990.90.750.820.980.960.64-0.350.540.660.40.620.910.750.690.930.840.970.940.930.920.550.740.520.07
0.320.270.190.150.30.290.16-0.080.260.250.40.180.160.390.440.180.210.280.340.250.180.520.37-0.050.39
0.690.830.410.490.650.730.49-0.590.50.770.620.180.530.850.850.540.60.730.790.570.750.50.840.790.17
0.940.850.80.890.960.90.49-0.190.460.680.910.160.530.60.460.990.90.90.870.930.950.260.60.410.13
0.760.810.410.550.720.820.62-0.660.620.650.750.390.850.60.870.60.70.810.830.610.730.690.990.640.16
0.690.770.470.310.650.720.57-0.520.370.630.690.440.850.460.870.480.550.720.760.550.650.650.820.690.0
0.960.860.820.890.970.910.53-0.190.450.670.930.180.540.990.60.480.880.910.880.970.950.260.60.440.09
0.880.850.660.820.880.90.37-0.350.560.80.840.210.60.90.70.550.880.870.860.830.90.310.680.330.27
0.980.940.650.850.970.990.64-0.530.670.710.970.280.730.90.810.720.910.870.980.90.950.590.80.640.12
0.970.980.640.850.940.970.65-0.520.660.770.940.340.790.870.830.760.880.860.980.870.950.60.820.660.23
0.950.860.850.830.970.890.51-0.170.410.690.930.250.570.930.610.550.970.830.90.870.930.290.620.450.07
0.970.960.760.870.960.940.52-0.350.530.820.920.180.750.950.730.650.950.90.950.950.930.360.720.590.19
0.480.49-0.050.380.430.60.63-0.790.760.210.550.520.50.260.690.650.260.310.590.60.290.360.670.580.13
0.750.790.40.570.710.80.6-0.640.630.640.740.370.840.60.990.820.60.680.80.820.620.720.670.620.19
0.560.670.220.440.520.630.77-0.650.490.330.52-0.050.790.410.640.690.440.330.640.660.450.590.580.62-0.16
0.120.23-0.070.330.080.12-0.29-0.190.40.490.070.390.170.130.160.00.090.270.120.230.070.190.130.19-0.16
Click cells to compare fundamentals

Biomarin Pharmaceutical Account Relationship Matchups

Biomarin Pharmaceutical fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets4.7B5.8B6.0B6.4B6.8B7.2B
Short Long Term Debt Total848.1M1.1B1.1B1.1B1.1B1.2B
Other Current Liab(13.0M)289.2M329.4M346.6M354.2M372.0M
Total Current Liabilities932.5M492.5M539.8M588.9M1.2B1.2B
Total Stockholder Equity3.1B4.1B4.3B4.6B5.0B5.2B
Property Plant And Equipment Net1.0B1.0B1.0B1.1B1.1B1.2B
Net Debt410.7M426.0M491.8M358.5M378.7M216.1M
Retained Earnings(1.7B)(861.6M)(925.7M)(789.2M)(621.6M)(652.6M)
Accounts Payable570.6M191.4M193.0M231.2M315.5M331.3M
Cash437.4M649.2M587.3M724.5M755.1M792.9M
Non Current Assets Total2.7B3.5B3.7B3.6B3.9B4.1B
Non Currrent Assets Other122.0M142.2M151.8M176.2M121.2M72.7M
Cash And Short Term Investments753.8M1.1B1.0B1.3B1.1B595.1M
Net Receivables377.4M448.4M373.4M461.3M633.7M665.4M
Common Stock Shares Outstanding179.0M191.7M182.9M189.0M191.6M127.6M
Liabilities And Stockholders Equity4.7B5.8B6.0B6.4B6.8B7.2B
Non Current Liabilities Total635.2M1.2B1.2B1.2B713.0M586.6M
Inventory680.3M698.5M776.7M894.1M1.1B1.2B
Other Current Assets130.7M129.9M110.4M104.5M141.4M148.5M
Other Stockholder Equity4.8B5.0B5.2B5.4B5.6B5.9B
Total Liab1.6B1.7B1.7B1.8B1.9B2.0B
Property Plant And Equipment Gross1.0B1.0B1.8B1.9B1.9B2.0B
Total Current Assets1.9B2.3B2.3B2.8B3.0B3.1B
Accumulated Other Comprehensive Income20.2M(16.1M)14.4M(3.9M)(38.6M)(36.7M)
Intangible Assets456.6M417.3M388.7M338.6M294.7M244.4M
Common Stock Total Equity178K180K182K184K211.6K126.8K
Short Term Investments316.4M416.2M426.6M567.0M318.7M276.3M
Common Stock180K182K184K186K189K133.2K
Other Assets612.0M1.6B1.6B1.6B1.8B1.9B
Long Term Debt486.2M1.1B1.1B1.1B593.1M553.3M
Property Plant Equipment1.0B1.0B1.0B1.1B1.3B1.3B
Other Liab98.1M174.3M113.7M73.5M84.5M81.8M
Net Tangible Assets2.5B3.5B3.7B4.1B4.7B4.9B
Retained Earnings Total Equity(1.7B)(1.7B)(861.6M)(925.7M)(833.1M)(874.8M)
Long Term Debt Total830.4M486.2M1.1B1.1B1.2B730.7M
Capital Surpluse4.7B4.8B5.0B5.2B6.0B3.7B
Long Term Investments412.0M285.5M507.8M333.8M611.1M353.3M

Biomarin Pharmaceutical Investors Sentiment

The influence of Biomarin Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Biomarin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biomarin Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biomarin Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Biomarin Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Biomarin Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biomarin Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biomarin Pharmaceutical's short interest history, or implied volatility extrapolated from Biomarin Pharmaceutical options trading.

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biomarin Stock

  0.64MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.87MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Biomarin Stock

  0.81MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.77EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.76MDWD Mediwound Downward RallyPairCorr
  0.63CLVRW Clever Leaves HoldingsPairCorr
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Biomarin Stock analysis

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.98
Earnings Share
0.87
Revenue Per Share
12.88
Quarterly Revenue Growth
0.202
Return On Assets
0.0163
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.